Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT04234113. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Study identification
- NCT ID
- NCT04234113
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- SOTIO Biotech AG
- Industry
- Enrollment
- 115 participants
Conditions and interventions
Conditions
- Anal Cancer
- Biliary Tract Cancer
- Bladder Cancer
- Cervical Cancer
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Melanoma
- Merkel Cell Carcinoma
- Mesothelioma
- Microsatellite Instability High
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Skin Squamous Cell Carcinoma
- Small-cell Lung Cancer
- Thymic Cancer
- Thyroid Cancer
- Triple Negative Breast Cancer
Interventions
- Nanrilkefusp alfa Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2019
- Primary completion
- Aug 30, 2024
- Completion
- Nov 26, 2024
- Last update posted
- Mar 26, 2026
2019 – 2024
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15216 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04234113, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04234113 live on ClinicalTrials.gov.